KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Raw Materials (2016 - 2022)

TherapeuticsMD filings provide 11 years of Raw Materials readings, the most recent being $1.9 million for Q3 2022.

  • On a quarterly basis, Raw Materials fell 44.19% to $1.9 million in Q3 2022 year-over-year; TTM through Sep 2022 was $1.9 million, a 44.19% decrease, with the full-year FY2021 number at $3.0 million, down 18.84% from a year prior.
  • Raw Materials hit $1.9 million in Q3 2022 for TherapeuticsMD, up from $434000.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $5.7 million in Q4 2019 to a low of $19400.0 in Q4 2018.
  • Median Raw Materials over the past 5 years was $3.6 million (2020), compared with a mean of $3.0 million.
  • Biggest five-year swings in Raw Materials: soared 29290.45% in 2019 and later plummeted 90.43% in 2022.
  • TherapeuticsMD's Raw Materials stood at $19400.0 in 2018, then soared by 29290.45% to $5.7 million in 2019, then plummeted by 34.27% to $3.7 million in 2020, then dropped by 18.84% to $3.0 million in 2021, then plummeted by 36.03% to $1.9 million in 2022.
  • The last three reported values for Raw Materials were $1.9 million (Q3 2022), $434000.0 (Q2 2022), and $4.4 million (Q1 2022) per Business Quant data.